公开(公告)号：CA3146302A1

公开(公告)日：2021-02-04

申请号：CA3146302

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  SASO KAYOKO

IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：CA3146292A1

公开(公告)日：2021-02-04

申请号：CA3146292

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI

IPC: C07K14/74

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：CA3133945A1

公开(公告)日：2020-10-01

申请号：CA3133945

申请日：2020-03-24

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/85 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a tyrosinase epitope, a MAGA-A1 epitope, a MART1 epitope, a MAGE-A3 epitope, or an SSX2 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：CA3132431A1

公开(公告)日：2020-09-10

申请号：CA3132431

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：CA3132242A1

公开(公告)日：2020-09-10

申请号：CA3132242

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020322247A1

公开(公告)日：2022-03-03

申请号：AU2020322247

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  SASO KAYOKO

IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MAGE-A2 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020319732A1

公开(公告)日：2022-03-03

申请号：AU2020319732

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  GUO TINGXI

IPC: C07K14/74 ,  A61K38/17 ,  A61P31/00 ,  A61P35/00 ,  C12N15/12

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：BR112021017464A2

公开(公告)日：2021-11-16

申请号：BR112021017464

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： SASO KAYOKO ,  MURATA KENJI ,  HIRANO NAOTO

IPC: A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/62 ,  C12N15/867 ,  G01N33/566

Abstract: receptores de células t e métodos de uso dos mesmos. a presente invenção refere-se a receptores de células t recombinantes capazes de se ligar a um epítopo ny-eso-1 e moléculas de ácido nucleico que codificam os mesmos. em algumas modalidades, as moléculas de ácido nucleico compreendem ainda uma segunda sequência de nucleotídeos, em que a segunda sequência de nucleotídeos ou o polipeptídeo codificado pela segunda sequência de nucleotídeos inibe a expressão de um tcr endógeno. outros aspectos da descrição são direcionados a vetores que compreendem a molécula de ácido nucleico e células que compreendem o tcr recombinante, a molécula de ácido nucleico ou o vetor. ainda outros aspectos da descrição são direcionados a métodos de uso dos mesmos. em algumas modalidades, os métodos compreendem o tratamento de um câncer em um sujeito em necessidade do mesmo.

公开(公告)号：SG11202109589VA

公开(公告)日：2021-10-28

申请号：SG11202109589V

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：AU2020231927A1

公开(公告)日：2021-09-30

申请号：AU2020231927

申请日：2020-03-03

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  MURATA KENJI ,  SASO KAYOKO

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.